Daunoxome
Daunoxome - General Information
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. [PubChem]
Pharmacology of Daunoxome
Daunoxome is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Daunoxome may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunoxome possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
Daunoxome for patients
Patient Information:
Daunorubicin is not recommended to patients who are pregnant and breast feeding because of the serious side
effects.
Check with your doctor immediately if you experience unusual bleeding or bruising, black stool, blood in
urine or stool.
Avoid contact with persons with infections. Check with you doctor immediately if you experience fever,
chill, cough or painful or painful or difficult urination.
Wash hands after you touch the medication.
Daunoxome Interactions
Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity. Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine. Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.
Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents.
Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity.
Daunoxome Contraindications
Cerubidine is contraindicated in patients who have shown a hypersensitivity to it.
Additional information about Daunoxome
Daunoxome Indication: For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Mechanism Of Action: Daunoxome has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunoxome forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Daunorubicin
Synonyms: Not Available
Drug Category: Antibiotics; Antineoplastic Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Daunorubicin: Acetyladriamycin; Anthracyline; Antibiotics From Streptomyces Coeruleorubidus; Cerubidin; Cerubidine; DM1; Daunamycin; Daunarubicinum; Daunoblastin; Daunomycin; Daunomycin Hydrochloride; Daunomycin, Hydrochloride; Daunorrubicina; Daunorubicin Hcl; Daunorubicin Hydrochloride; Daunorubicin, Hydrochloride; Daunorubicine; Daunorubicinum [Inn-Latin]; Daunoxome; Leukaemomycin C; Ondena; Rcra Waste No. U059; Rp 13057 Hydrochloride; Rubidomycin; Rubidomycin Hydrochloride; Rubomycin C;
Absorption: Not Available
Toxicity (Overdose): LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV)
Protein Binding: 97% binding-albumin
Biotransformation: Hepatic
Half Life: 18.5 hours
Dosage Forms of Daunoxome: Powder, for solution Intravenous
Chemical IUPAC Name: (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
Chemical Formula: C27H29NO10
Daunorubicin on Wikipedia: https://en.wikipedia.org/wiki/Daunorubicin
Organisms Affected: Humans and other mammals
